Come up with a name for your new list and we'll add to it:
Neurolixis raised a round of funding on January 25, 2018. Investors include
Parkinson's Disease Society of the United Kingdom.
Neurolixis is an early-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of human central nervous system diseases including Parkins…